COVID-19 Antibody Detecting Rapid Diagnostic Tests (COVID-19 Ab RDTs) are the preferred tool for SARS-CoV-2 seroprevalence studies, particularly in low- and middle-income countries. The present study challenged COVID-19 Ab RDTs with pre-pandemic samples of patients exposed to tropical pathogens. A retrospective study was performed on archived serum ( n = 94) and EDTA whole blood ( n = 126) samples obtained during 2010–2018 from 196 travelers with malaria ( n = 170), schistosomiasis ( n = 25) and dengue ( n = 25). COVID-19 Ab RDTs were selected based on regulatory approval status, independent evaluation results and detecting antigens. Among 13 COVID-19 Ab RDT products, overall cross-reactivity was 18.5%; cross-reactivity for malaria, schistosomiasis and dengue was 20.3%, 18.1% and 7.5%, respectively. Cross-reactivity for current and recent malaria, malaria antibodies, Plasmodium species and parasite densities was similar. Cross-reactivity among the different RDT products ranged from 2.7% to 48.9% (median value 14.5%). IgM represented 67.9% of cross-reactive test lines. Cross-reactivity was not associated with detecting antigens, patient categories or disease (sub)groups, except for schistosomiasis (two products with ≥60% cross-reactivity). The high cross-reactivity for malaria, schistosomiasis and—to a lesser extent—dengue calls for risk mitigation when using COVID-19 Ab RDTs in co-endemic regions.
【저자키워드】 COVID-19, SARS-CoV-2, cross-reactivity, 【초록키워드】 antibodies, IgM, Test, risk, malaria, Regulatory, Retrospective study, serum, SARS-CoV-2 seroprevalence, RDT, Whole blood, Patient, Rapid, antigens, Pathogens, disease, RDTs, Schistosomiasis, cross-reactive, approval, EDTA, Plasmodium, median value, regions, tropical, independent, selected, was performed, category, ranged, 【제목키워드】 Test, Dengue, Rapid, show, Sample,